Every AI express, investors ask questions on the investor interaction platform: is blood products in short supply now? If it is? It must be the market that determines the price, but it is impossible to reduce the price sharply because of centralized purchase. Why is the market so afraid of centralized purchase?
Hualan Biological Engineering Inc(002007) (002007. SZ) said on the investor interaction platform on February 26 that at present, the overall supply of blood products is still in short supply.
